Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

VANCOUVER-Inex Pharmaceuticals Corporation has announced positive results from a pivotal phase II/III clinical trial evaluating its lead anticancer product Onco TCS (liposomal vincristine) as single-agent therapy for relapsed aggressive non-Hodgkin’s lymphoma. The trial results will form the basis for a New Drug Application seeking approval for marketing from the US Food and Drug Administration (FDA). The 102 study patients had received an average of four other regimens, and 75% had resistant disease. The overall response rate with Onco TCS was 24%, including five complete responses.

VANCOUVER—Inex Pharmaceuticals Corporation has announced positive results from a pivotal phase II/III clinical trial evaluating its lead anticancer product Onco TCS (liposomal vincristine) as single-agent therapy for relapsed aggressive non-Hodgkin’s lymphoma. The trial results will form the basis for a New Drug Application seeking approval for marketing from the US Food and Drug Administration (FDA). The 102 study patients had received an average of four other regimens, and 75% had resistant disease. The overall response rate with Onco TCS was 24%, including five complete responses.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content